Ethos Discovery Announces Launch of Innovative Clinical Trials for Canine SepsisMay 27, 2021
Woburn, MA — May 27, 2021: Ethos Discovery today announced the launch of a several new clinical trials for dogs with septic peritonitis that seek to deliver novel diagnostic and therapeutic innovations to aid in the treatment of these patients.
Sepsis is a common reason for dogs to present to the emergency room. Sepsis is the result of an infection that enters the bloodstream and causes a severe inflammatory reaction, leading to negative effects throughout the body. The mortality rate for sepsis can be over 50%, and even though it has been heavily researched over the last several decades, there have not been significant improvements in patient survival. This persistently high mortality highlights the numerous unmet needs associated with the diagnosis and treatment of sepsis.
Ethos Discovery has recently launched multiple prospective clinical trials in the area of sepsis in an effort to provide solutions to these unmet needs. “This diverse portfolio utilizes multiple approaches towards developing novel diagnostic and therapeutic solutions to improve how we treat our septic canine patients,” said Chand Khanna, DVM, Ph.D., DACVIM (Oncology), President, Ethos Discovery and Chief Scientific Officer, Ethos Veterinary Health.
The Ethos Discovery sepsis portfolio includes several scientific advances to help patients through improved diagnosis, patient prognostication, and novel treatment approaches. “The translation of this scientific knowledge into improved care for our patients is a highly inspiring part of my work at Ethos”, said Samuel Stewart, DVM, DACVECC, Science Commercialization Fellow, Ethos Veterinary Health. Dr. Stewart added, “This portfolio involves state of the art science, including next generation sequencing of causative pathogens, transcriptomic biomarker discovery, and biomarker-driven therapeutic tailoring, to name a few of the planned approaches.”
Ethos Discovery seeks to conduct clinical trials that deliver innovations which will provide solutions to unmet needs in the daily practice of how veterinarians care for their patients. Through its priorities in sepsis discussed above, Ethos Discovery aims to reduce the sepsis mortality rate and provide more hope to the owners of dogs with sepsis.
# # #
About Ethos Discovery
Ethos Discovery is a 501(c)3 nonprofit organization devoted to developing innovative medical treatments and tests that benefit both pets and humans. Through targeted research, clinical trials, and the delivery of advanced veterinary care, we seek to address unmet clinical needs to improve health outcomes for humans and animals with complex medical problems.
Ethos Discovery is uniquely positioned, with the support of Ethos Veterinary Health, to reach patients and doctors nationally and to partner with key international leaders in their field. This flexibility provides us the opportunity to pursue impactful research that will make a difference where it is most important, within clinical hospitals and for patients and families. Scientific Programs are currently focused on: Sarcoma, Sepsis, Inflammatory Brain Disease, Dysbiosis, Therapeutics, and Surgical Innovations.